top of page
DAVA Oncology Meetings Innovation
Join us to get inspired!
Whistler 2022: Pro Gallery
10TH WHISTLER GLOBAL SUMMIT
ON HEMATOLOGIC MALIGNANCIES
MARCH 29, 2023 To APRIL 2, 2023
4599 Chateau Boulevard,
Whistler-British Columbia V8E 0Z5,
Canada
_edited_edited.jpg)
_edited_edited.jpg)
Whistler 2022: Speakers
 • Non-covalent BTK inhibitors • The role of BTK inhibitors in 2022 • Emerging drugs targeting PI3K signaling • Emerging drug classes in CLL • New BTK inhibitor safety data • Cellular therapies for CLL • Emerging antibody-drug conjugates • Emerging bispecific antibodies • Agents targeting apoptosis • Novel SYK inhibitors |  • Triple-class refractory MM • Relapsed/refractory MM • Waldenström’s macroglobulinemia • Decision-making using MRD • Emerging cellular therapies • BCMA, CD3, CD38, CD19, and emerging bispecific antibody epitopes • Novel antibody-drug conjugates |  • Follicular lymphoma • Diffuse large B-cell lymphoma • Hodgkin’s lymphoma • Low-grade lymphoma • MCL and MZL • Next generation PI3K pathway inhibitors • Emerging EZH2 inhibitors • Cellular therapy • New radio-immunoconjugates and ADCs • Bispecific antibodies |  • Next generation checkpoint inhibitors: CD47, TIM-3 • CD33, CD123, and other emerging Antibody-drug conjugates epitopes • Emerging bispecific antibodies • Novel agents targeting apoptosis • FLT3 and AXL inhibitors • New differentiating agents • Novel combination therapies • Updates on CAR-T therapies |
|---|
Chronic Lymphocytic Leukemia
Multiple Myeloma
Lymphoma
Leukemia and MDS
SCHEDULE AT GLANCE
bottom of page